Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Can’t Be More Risky. Short Interest Increased

November 10, 2018 - By Vivian Park

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Logo

Investors sentiment decreased to 1 in Q2 2018. Its down 0.50, from 1.5 in 2018Q1. It is negative, as 7 investors sold Actinium Pharmaceuticals, Inc. shares while 6 reduced holdings. 9 funds opened positions while 4 raised stakes. 6.70 million shares or 63.68% less from 18.45 million shares in 2018Q1 were reported.
California Employees Retirement accumulated 40,000 shares. Boothbay Fund Management Lc holds 0% or 25,764 shares in its portfolio. Citadel Advsrs Lc owns 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 33,430 shares. Morgan Stanley owns 16,348 shares for 0% of their portfolio. 104,186 are owned by Panagora Asset Management Inc. 469,578 were accumulated by Blackrock. Da Davidson Com reported 58,000 shares. Walleye Trading Ltd Com reported 75,200 shares stake. Geode Capital Mgmt Ltd holds 0% or 312,355 shares in its portfolio. Oregon-based Baker Ellis Asset Mgmt Ltd has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Barclays Public Limited Liability Company invested 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Dowling & Yahnke Llc owns 22,870 shares for 0% of their portfolio. Intrust Comml Bank Na holds 0% or 20,000 shares. 60,000 are held by Malaga Cove Limited Liability Company. Moreover, Millennium Mngmt Ltd has 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 33,555 shares.

The stock of Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) registered an increase of 5.24% in short interest. ATNM’s total short interest was 3.81M shares in November as published by FINRA. Its up 5.24% from 3.62M shares, reported previously. With 619,100 shares average volume, it will take short sellers 6 days to cover their ATNM’s short positions.

The stock increased 0.10% or $0.0006 during the last trading session, reaching $0.5819. About 687,668 shares traded. Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has risen 4.92% since November 10, 2017 and is uptrending. It has underperformed by 10.70% the S&P500.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $66.74 million. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Company’s lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>